Last viewed:
GOVX
Prices are updated after-hours
GOVX
|
$1.54
1.27%
35K
|
Health Technology
(0.0% 1d)
(-18.9% 1m)
(146.0% 1y)
(0.0% 2d)
(-0.6% 3d)
(1.3% 7d)
(6.31%
volume)
Earnings Calendar: 2023-11-08
Market Cap: $ 3,554,796
http://www.geovax.com
Sec
Filling
|
Patents
| 6 employees
(US) GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and cancer using its novel vaccine platform. It focuses on human immunodeficiency virus, zika virus, hemorrhagic fever viruses, and malaria. The company was founded by Harriet Latham Robinson and Donald G. Hildebrand on September 9, 2006 and is headquartered in Smyrna, GA.
vaccine
cancer
immunotherapy
infectious disease
smallpox
add to watch list
Paper trade
email alert is off
Press-releases
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
Published: 2024-03-28
(Crawled : 13:00)
- globenewswire.com
GOVX
|
$1.54
1.27%
35K
|
Health Technology
| -18.95%
| O: 4.21%
H: 1.01%
C: 1.01%
cm04
covid-19
vaccine
congress
world
GeoVax to Present at the 36th Annual Roth Conference
Published: 2024-03-12
(Crawled : 13:00)
- globenewswire.com
GOVX
|
$1.54
1.27%
35K
|
Health Technology
| -28.04%
| O: 0.0%
H: 4.21%
C: -3.27%
conference
GeoVax to Present at the 2024 BIO CEO & Investor Conference
Published: 2024-02-19
(Crawled : 14:00)
- globenewswire.com
GOVX
|
$1.54
1.27%
35K
|
Health Technology
| Email alert
Add to watchlist
ceo
conference
GeoVax Announces Multiple Patent Issuances and Allowances
Published: 2024-02-13
(Crawled : 14:00)
- globenewswire.com
GOVX
|
$1.54
1.27%
35K
|
Health Technology
| -41.67%
| O: 2.65%
H: 0.0%
C: -6.27%
patent
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Published: 2024-02-06
(Crawled : 14:00)
- globenewswire.com
GOVX
|
$1.54
1.27%
35K
|
Health Technology
| -39.13%
| O: 2.77%
H: 2.69%
C: 1.92%
cm04
covid-19
vaccine
universal
geo-cm04s1
positive
trial
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
Published: 2024-01-29
(Crawled : 14:00)
- globenewswire.com
GOVX
|
$1.54
1.27%
35K
|
Health Technology
| 443.21%
| O: 5.82%
H: 0.0%
C: -13.3%
nasdaq
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
Published: 2024-01-08
(Crawled : 14:00)
- globenewswire.com
GOVX
|
$1.54
1.27%
35K
|
Health Technology
| 316.67%
| O: 0.11%
H: 4.05%
C: 0.0%
medical
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
Published: 2024-01-04
(Crawled : 00:00)
- biospace.com/
GOVX
|
$1.54
1.27%
35K
|
Health Technology
| 311.43%
| O: 4.19%
H: 0.0%
C: -6.41%
gedeptin
cancer
trial
advanced
GeoVax Announces Issuance of Malaria Vaccine Patent
Published: 2024-01-03
(Crawled : 14:00)
- globenewswire.com
GOVX
|
$1.54
1.27%
35K
|
Health Technology
| 316.22%
| O: 2.7%
H: 5.26%
C: -1.5%
patent
vaccine
malaria
Novanta completes acquisition of Motion Solutions – Financial Post
Published: 2024-01-02
(Crawled : 22:00)
- spacfeed.com
GOVX
|
$1.54
1.27%
35K
|
Health Technology
| 316.22%
| O: 2.7%
H: 5.26%
C: -1.5%
acquisition
solutions
financial
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount